Related Experiment Video
Updated: Jun 13, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
TNF polymorphisms in patients with Behçet disease: a meta-analysis
Zahi Touma1, Chantal Farra, Ayad Hamdan
1Department of Internal Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.
Archives of Medical Research
|May 18, 2010
Summary
This meta-analysis found significant associations between specific tumor necrosis factor (TNF) gene polymorphisms and Behçet's disease. The -1031C, -238A, and -857T variants are linked to this inflammatory condition.
Area of Science:
- Genetics
- Immunology
- Molecular Biology
Background:
- Behçet's disease is a complex inflammatory disorder.
- Polymorphisms in the tumor necrosis factor (TNF) gene have been investigated for their role in Behçet's disease susceptibility.
- Previous studies explored various TNF gene locations (-308, -238, -863, -857, -1031) across different ethnic groups.
Purpose of the Study:
- To conduct a meta-analysis examining the association between specific tumor necrosis factor (TNF) gene promoter polymorphisms and Behçet's disease.
- To consolidate evidence from existing literature to determine the overall impact of TNF gene variations on disease risk.
Main Methods:
- A comprehensive literature search was conducted using MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials.
- Original studies published in English before October 31, 2009, were included.
- Random-effects models were used to calculate pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was assessed using Cochrane Q test and I(2) statistics.
Main Results:
- Ten studies met the inclusion criteria, involving 13 initially identified studies.
- Significant associations were found between Behçet's disease and TNF gene polymorphisms at locations -1031C (OR = 1.35, 95% CI = 1.09-1.68), -238A (OR = 1.51, 95% CI = 1.12-2.04), and -857T (OR = 0.76, 95% CI = 0.58-0.98).
- No statistically significant associations were observed for the -308A and -863A polymorphisms.
Conclusions:
- Behçet's disease is associated with specific tumor necrosis factor (TNF) gene promoter polymorphisms, namely -1031C, -238A, and -857T.
- These findings highlight the role of TNF gene variations in the susceptibility to Behçet's disease across diverse ethnic populations.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...